Yi Xiaojiao, Wang Fugen, Feng Yan, Zhu Junfeng, Wu Yongjiang
Department of Pharmacy, Affiliated Hangzhou Xixi Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Department of Pharmacy, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China.
Front Pharmacol. 2022 Aug 22;13:929302. doi: 10.3389/fphar.2022.929302. eCollection 2022.
Doxorubicin (DOX) is a potent chemotherapeutic agent that is used against various types of human malignancies. However, the associated risk of cardiotoxicity has limited its clinical application. Danhong injection (DHI) is a Chinese medicine with multiple pharmacological activities and is widely used for treating cardiovascular diseases. The aim of the present study was to evaluate the potential protective effect of DHI on DOX-induced cardiotoxicity and to investigate the possible underlying mechanisms. First, a sensitive and reliable HPLC-ESI-Q-TOF-MS/MS method was developed to comprehensively analyze the chemical compositions of DHI. A total of 56 compounds were identified, including phenolic acids, tanshinones, and flavonoids. Then, a DOX-induced chronic cardiotoxicity rat model was established to assess the therapeutic effect of DHI. As a result, DHI administration prevented the reduction in body weight and heart weight, and improved electrocardiogram performance. Additionally, the elevated levels of serum biochemical indicators were reduced, and the activities of oxidative enzymes were restored in the DOX-DHI group. Network pharmacology analysis further revealed that these effects might be attributed to 14 active compounds (, danshensu, salvianolic acid A, salvianolic acid B, rosmarinic acid, and tanshinone IIA) and 15 potential targets (, CASP3, SOD1, NOS3, TNF, and TOP2A). The apoptosis pathway was highly enriched according to the KEGG analysis. Molecular docking verified the good binding affinities between the active compounds and the corresponding apoptosis targets. Finally, experimental validation demonstrated that DHI treatment significantly increased the Bcl-2 level and suppressed DOX-induced Bax and caspase-3 expression in rat heart tissue. Furthermore, DHI treatment obviously decreased the apoptosis rate of DOX-treated H9c2 cells. These results indicate that DHI attenuated DOX-induced cardiotoxicity via regulating the apoptosis pathway. The present study suggested that DHI is a promising agent for the prevention of DOX-induced cardiotoxicity.
多柔比星(DOX)是一种有效的化疗药物,用于治疗各种类型的人类恶性肿瘤。然而,其相关的心脏毒性风险限制了其临床应用。丹红注射液(DHI)是一种具有多种药理活性的中药,广泛用于治疗心血管疾病。本研究的目的是评估DHI对DOX诱导的心脏毒性的潜在保护作用,并探讨其可能的潜在机制。首先,开发了一种灵敏可靠的HPLC-ESI-Q-TOF-MS/MS方法,用于全面分析DHI的化学成分。共鉴定出56种化合物,包括酚酸、丹参酮和黄酮类化合物。然后,建立DOX诱导的慢性心脏毒性大鼠模型,以评估DHI的治疗效果。结果显示,给予DHI可防止体重和心脏重量下降,并改善心电图表现。此外,DOX-DHI组血清生化指标升高水平降低,氧化酶活性恢复。网络药理学分析进一步表明,这些作用可能归因于14种活性化合物(丹酚酸、丹参素、丹酚酸A、丹酚酸B、迷迭香酸和丹参酮IIA)和15个潜在靶点(CASP3、SOD1、NOS3、TNF和TOP2A)。根据KEGG分析,凋亡途径高度富集。分子对接验证了活性化合物与相应凋亡靶点之间具有良好的结合亲和力。最后,实验验证表明,DHI处理可显著提高大鼠心脏组织中Bcl-2水平,并抑制DOX诱导的Bax和caspase-3表达。此外,DHI处理明显降低了DOX处理的H9c2细胞的凋亡率。这些结果表明,DHI通过调节凋亡途径减轻了DOX诱导的心脏毒性。本研究表明,DHI是预防DOX诱导的心脏毒性的一种有前景的药物。